Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing
Executive Summary
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
You may also be interested in...
Calithera Drops Development Of Lead Candidate Telaglenastat
Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.
Takeda Buys Out Partner GammaDelta In Cell Therapy Push
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
Strides Completes Acquisition Of Endo US Facility And ANDAs
Two months after announcing the deal, Strides Pharma Science has closed its acquisition of a US manufacturing site and basket of ANDAs from Endo, doubling the company’s burgeoning US business and providing much-needed cash to the US-based company.